Eledon Pharmaceuticals, Inc.
ELDNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Mar 16, 2026 | Leerink Partners | Thomas Smith | $5.00(+83%) | $2.73 | StreetInsider |
| Jun 18, 2025 | H.C. Wainwright | Yi Chen | $9.00(+224%) | $2.78 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Guggenheim | maintain | Buy | Nov 18, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 10, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 13, 2023 |
| HC Wainwright & Co. | maintain | Buy | Oct 24, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Aug 22, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 26, 2023 |
| SVB Leerink | maintain | Outperform | Jun 1, 2022 |
| HC Wainwright & Co. | maintain | Buy | Nov 24, 2021 |
| SVB Leerink | maintain | Outperform | Apr 27, 2021 |
| Cantor Fitzgerald | maintain | Overweight | Mar 23, 2021 |
| SVB Leerink | maintain | Outperform | Feb 8, 2021 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.20| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.27 | $-0.16 | — | — |
| May 13, 2026 | $-0.33 | $-0.22 | — | — |
| Mar 19, 2026 | $-0.10 | $-0.20 | — | — |
| Nov 14, 2025 | $-0.21 | $-0.22 | — | — |
| Aug 14, 2025 | $-0.13 | $-0.23 | — | — |
| May 14, 2025 | $-0.08 | $-0.28 | — | — |
| Mar 20, 2025 | $-0.64 | $-0.32 | $192.0K | — |
| Nov 12, 2024 | $-0.32 | $-0.30 | — | — |
News
Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence Statistically significant improvement on the KDQOL-SF Symptoms and Problems Scale among tegoprubart-treated patients through 12 months following kidney transplantation versus tacrolimus Results further validate the differentiated clinical profile of tegoprubart and potential to transform sta…
IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephrology Kidney Week 2026 Annual Meeting taking place in Denver, CO, from October 21-25, 2026.
Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58 mL/min/1.73 m²) at month 24 No rejections occurred in the tegoprubart arm beyond six months post-transplant, compared with seven in the tacrolimus arm Tegoprubart granted U.S. FDA Fast Track designation for the prevention of rejection in kidney transplantation Phase 3 LEGACY study expe…
IRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection will take place at the upcoming International Congress of The Transplantation Society in Sydney, Australia, from September 20–23, 2026.
IND submitted to FDA for Eledon-sponsored, registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes First patients enrolled in new investigator-initiated study of tegoprubart in patients with renal dysfunction receiving an islet cell transplant First patient dosed under compassionate use of tegoprubart for conversion from tacrolimus in islet cell transplant recipients with calcineurin inhibitor related kidney dysfunction First patients dosed under compa…
ADAR1 Capital Management LLC purchased a new position in Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 647,812 shares of the company's stock, valued at approximately $2,552,000. ADAR1 Capital Management LLC owned 0.84% of Eledon
Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data presented at ATC 2026 demonstrated sustained higher kidney function and improved patient-reported outcomes with tegoprubart compared with tacrolimus Updated islet cell transplantation data presented at ADA 2026 showed 100% insulin independence in all 12 patients with type 1 diabetes Cash, cash equivalent…